Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma
NCT ID: NCT02679482
Last Updated: 2016-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
36 participants
OBSERVATIONAL
2014-09-30
2016-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multicenter Glaucoma Study Investigating Standalone Canaloplasty
NCT05786196
Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty
NCT02327312
Micropulse Laser Trabeculoplasty (532nm) Versus Conventional Laser Trabeculoplasty (532nm)
NCT01788319
Goniocurettage as First Choice of Surgical Treatment in Chronic Open-Angle Glaucoma: Outcomes and Complications
NCT01511094
Combined Phacoemulsification and Diode Laser Therapy in Chronic Angle Closure Glaucoma
NCT05576493
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is strictly observational, that's why the laser procedure is covered by the national health insurance of each patient, as well the complications due to the same procedure. An evaluation pre trabeculoplasty and a consecutive 5 visits will be perform as follows:
Visit 0 - Pre-procedure visit: the subjects that will undergo laser trabeculoplasty either Selective laser or PASCAL laser will be invited to participate and an informed consent will be carried out. The information concerting to demographics characteristics (study eye, age, gender and ethnicity), clinical characteristics (date of glaucoma diagnosis, number of medications used to treat glaucoma, time of use of actually anti-glaucomatous topical medication) and slit lamp and ophthalmoscopy examination (corneal aspect, iris color, pupil gonioscopy, intraocular pressure, lens status, vitreous cells, vertical C/D ratio, optic nerve edge, rim characteristic \[ISNT pattern\], peripapilar atrophy, state of fovea, state of peripheral retina and state of choroid for both eyes) will be extracted and recorded on respective case report form (CRF). The data will be scored according to the grading criteria outlined below:
Study eye: the eye under the follow-up 0 - Right eye 1 - Left eye
Geder: the state of being male or female 0 - Male 1 - Female
Ethnicity: the fact or state of belonging to a social group that has a common national or cultural tradition.
0 - Hispanic
1. \- Black
2. \- White
3. \- Asian
Number of medications used: anti-glaucoma medication used by the patient 0 - 0
1. \- 1
2. \- 2
3. \- 3
4. \- 4
Corneal aspect: state in which the cornea is at baseline 0 - Normal 1 - Anormal
Iris color: iris pigmentation 0 - Light
1. \- Medium
2. \- Dark
Gonioscopy (Shaffer classification): amplitude of irido-corneal angle maseure by poster lens and noted by the Shaffer scale on each quadrant superior, nasal, temporal and inferor angle 0 - 0
1. \- 1
2. \- 2
3. \- 3
4. \- 4
Intraocular pressure: pressure inside the eye measured in millimeters of mercury Value in mmhg, measure with Goldman tonometer
Lens status: clouding of the lens Nuclear, Subcapsular and Cortical 0 - 0
1. \- 1
2. \- 2
3. \- 3
4. \- 4
Vitreous cells: number of cells per milimeter in the vitreous cavity 0 - 0 1 - traces 2 - +1 3 - +2 4 - +3 5 - +4
Vertical C/D ratio: relation between cup and optic nerve disc 0 - 0.1
1. \- 0.2
2. \- 0.3
3. \- 0.4
4. \- 0.5
5. \- 0.6
6. \- 0.7
7. \- 0.8
8. \- 0.9
9. \- 1.0
Optic nerve edge: regularly over the optic disc 0 - Regular
1 - Irregular
Rim characteristic \[ISNT pattern\]: reduction pattern in the thickness of neural ring 0 - Conserved 1 - Not conserved
Peripapilar atrophy: presence of atrophy over the disc 0 - Alfa
1 - Beta 3 - Not apply
State of fovea: normality of the fovea 0 - normal
1 - abnormal
State of peripheral retina: state of the peripheral retina 0 - normal
1 - abnormal
State of choroid: choroidal health 0 - normal
1 - abnormal
After the visit 0, a 5 consecutive visits will be performed: for 1 day, 1 week, 1 month, 3 months and 6 months after the procedure. Identical data will be extracted, ophthalmological examination data, slit lamp exam, and the computerized visual fields (CVF) (CVF only at 3 and 6 months).
One member of the investigation team will collect all information during the follow-up time, and a second one member will review and collate data.
Statistical analysis will be performed in SPSS version 21. Univariate analyzes will perform; for categorical variables, frequency distribution will be made and reported in percentage, for the quantitative variables a measure of central tendency and dispersion will be made (mean, standard deviation and range) will calculate according to the relevance for each variable analyzed. Demographics such as age and gender variables will be described. For bivariate analysis comparing polytomous qualitative and quantitative variables (evolution of intraocular pressure with the type of trabeculoplasty used, number of antihypertensive medications required after the procedure with the type of trabeculoplasty, quantification of cellularity in the anterior chamber with type of trabeculoplasty) using parametric statistical analysis with ANOVA for independent samples and nonparametric with Kruskal-Wallis test. Also comparison of quantitative variables with quantitative variables (intraocular pressure before treatment and evolution of intraocular pressure after treatment) will be performed using the parametric inferential statistical Pearson correlation analysis and for nonparametric a Spearman correlation will be made. Finally, compare qualitative variables with qualitative variables (presence of peak intraocular pressure with type of laser trabeculoplasty performed) using the non-parametric statistical analysis Chi square test, Fisher exact test and Mac Nemar will make.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Selective laser trabeculoplasty (SLT)
Patients who underwent to Selective laser trabeculoplasty
No interventions assigned to this group
Pattern laser trabeculoplasty (PLT)
Patients who underwent to Pattern laser trabeculoplasty
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Best distant visual acuity, better than or equal to 20/200
* Diagnosis of primary open-angle glaucoma, pseudoexfoliation glaucoma or pigmentary glaucoma, with open angles by Posner lens gonioscopy
* Intraocular pressure ≥ 20 mmHg, with medical treatment, as monotherapy or combination therapy.
* Previous computerized visual field within the six months previous performing trabeculoplasty
* Patients who understand and sign the informed consent
* Patient diagnosed with open-angle glaucoma who will undergo selective laser trabeculoplasty (SLT) with an amplitud of 360 degrees, or laser trabeculaplastia in pattern (PASCAL-Pattern Scan Laser) with an amplitud of 360 degrees. Made at initial session or in two 7 days separate sessions (each with session with an amplitude of180 degrees)
Exclusion Criteria
* Previous history of surgery for glaucoma management, except peripheral iridotomy
* Corneal disease that does not allow the use of applanation tonometer nor an accurate measurement of intraocular pressure
* Corneal disease which prevents adequate visualization of trabeculo by gonioscopy lens
* Use of topical or systemic steroids
* Concomitant participation in another study
* Coexistence of other ocular pathology different than cataract.
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundación Oftalmológica Nacional
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sandra Belalcazar, MD
Role: PRINCIPAL_INVESTIGATOR
Fundacion Oftalmológica Nacional
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fundacion Oftalmológica Nacional
Bogotá, Bogota D.C., Colombia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Wang W, He M, Zhou M, Zhang X. Selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with open-angle glaucoma: a systematic review and meta-analysis. PLoS One. 2013 Dec 19;8(12):e84270. doi: 10.1371/journal.pone.0084270. eCollection 2013.
Wise JB, Witter SL. Argon laser therapy for open-angle glaucoma. A pilot study. Arch Ophthalmol. 1979 Feb;97(2):319-22. doi: 10.1001/archopht.1979.01020010165017. No abstract available.
Barkana Y, Belkin M. Selective laser trabeculoplasty. Surv Ophthalmol. 2007 Nov-Dec;52(6):634-54. doi: 10.1016/j.survophthal.2007.08.014.
Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res. 1995 Apr;60(4):359-71. doi: 10.1016/s0014-4835(05)80093-4.
Sanghvi C, McLauchlan R, Delgado C, Young L, Charles SJ, Marcellino G, Stanga PE. Initial experience with the Pascal photocoagulator: a pilot study of 75 procedures. Br J Ophthalmol. 2008 Aug;92(8):1061-4. doi: 10.1136/bjo.2008.139568. Epub 2008 Jun 27.
Sambhara D, Aref AA. Glaucoma management: relative value and place in therapy of available drug treatments. Ther Adv Chronic Dis. 2014 Jan;5(1):30-43. doi: 10.1177/2040622313511286.
Buys YM. Economics of selective laser trabeculoplasty as primary therapy for glaucoma. Can J Ophthalmol. 2006 Aug;41(4):419-20. doi: 10.1016/S0008-4182(06)80001-3. No abstract available.
Quigley HA. Glaucoma. Lancet. 2011 Apr 16;377(9774):1367-77. doi: 10.1016/S0140-6736(10)61423-7. Epub 2011 Mar 30.
Samples JR, Singh K, Lin SC, Francis BA, Hodapp E, Jampel HD, Smith SD. Laser trabeculoplasty for open-angle glaucoma: a report by the american academy of ophthalmology. Ophthalmology. 2011 Nov;118(11):2296-302. doi: 10.1016/j.ophtha.2011.04.037. Epub 2011 Aug 17.
Krasnov MM. [Laser puncture of the anterior chamber angle in glaucoma (a preliminary report)]. Vestn Oftalmol. 1972;3:27-31. No abstract available. Russian.
Van Buskirk EM, Pond V, Rosenquist RC, Acott TS. Argon laser trabeculoplasty. Studies of mechanism of action. Ophthalmology. 1984 Sep;91(9):1005-10. doi: 10.1016/s0161-6420(84)34197-5.
Alvarado JA, Alvarado RG, Yeh RF, Franse-Carman L, Marcellino GR, Brownstein MJ. A new insight into the cellular regulation of aqueous outflow: how trabecular meshwork endothelial cells drive a mechanism that regulates the permeability of Schlemm's canal endothelial cells. Br J Ophthalmol. 2005 Nov;89(11):1500-5. doi: 10.1136/bjo.2005.081307.
Bradley JM, Anderssohn AM, Colvis CM, Parshley DE, Zhu XH, Ruddat MS, Samples JR, Acott TS. Mediation of laser trabeculoplasty-induced matrix metalloproteinase expression by IL-1beta and TNFalpha. Invest Ophthalmol Vis Sci. 2000 Feb;41(2):422-30.
The Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. The Glaucoma Laser Trial Research Group. Ophthalmology. 1990 Nov;97(11):1403-13.
Bylsma SS, Samples JR, Acott TS, Van Buskirk EM. Trabecular cell division after argon laser trabeculoplasty. Arch Ophthalmol. 1988 Apr;106(4):544-7. doi: 10.1001/archopht.1988.01060130590044.
Pham H, Mansberger S, Brandt JD, Damji K, Ramulu PY, Parrish RK. Argon laser trabeculoplasty versus selective laser trabeculoplasty. Surv Ophthalmol. 2008 Nov-Dec;53(6):641-6. doi: 10.1016/j.survophthal.2008.08.020.
Zhao JC, Grosskreutz CL, Pasquale LR. Argon versus selective laser trabeculoplasty in the treatment of open angle glaucoma. Int Ophthalmol Clin. 2005 Fall;45(4):97-106. doi: 10.1097/01.iio.0000176370.01511.6e. No abstract available.
Wang H, Cheng JW, Wei RL, Cai JP, Li Y, Ma XY. Meta-analysis of selective laser trabeculoplasty with argon laser trabeculoplasty in the treatment of open-angle glaucoma. Can J Ophthalmol. 2013 Jun;48(3):186-92. doi: 10.1016/j.jcjo.2013.01.001.
Related Links
Access external resources that provide additional context or updates about the study.
Selective laser trabeculoplasty versus argon laser trabeculoplasty in patients with open-angle glaucoma: a systematic review and meta-analysis
Argon laser therapy for open-angle glaucoma. A pilot study
Selective laser trabeculoplasty
Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions
Initial experience with the Pascal photocoagulator: a pilot study of 75 procedures
Glaucoma management: relative value and place in therapy of available drug treatments
Economics of selective laser trabeculoplasty as primary therapy for glaucoma
Laser trabeculoplasty for open-angle glaucoma: a report by the american academy of ophthalmology
Laser puncture of the anterior chamber angle in glaucoma (a preliminary report)
Argon laser trabeculoplasty. Studies of mechanism of action
A new insight into the cellular regulation of aqueous outflow: how trabecular meshwork endothelial cells drive a mechanism that regulates the permeability of Schlemm's canal endothelial cells
Mediation of laser trabeculoplasty-induced matrix metalloproteinase expression by IL-1beta and TNFalph
Results of argon laser trabeculoplasty versus topical medicines. The Glaucoma Laser Trial Research Group
Trabecular cell division after argon laser trabeculoplasty
Argon laser trabeculoplasty versus selective laser trabeculoplasty
Argon versus selective laser trabeculoplasty in the treatment of open angle glaucom
Meta-analysis of selective laser trabeculoplasty with argon laser trabeculoplasty in the treatment of open-angle glaucoma
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FONCI6001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.